SAN JOSE, CA--(September 18, 2017) - ITUS Corporation (NASDAQ: ITUS), today announced that the United States Patent and Trademark Office ("USPTO") has issued U.S. Patent 9,739,783, to inventors Dr. Amit Kumar, Chief Executive Officer, and John Roop, VP of Engineering, of ITUS Corporation. ITUS's early cancer detection technology is being developed by its wholly owned subsidiary, Anixa Diagnostics Corporation.

 

Dr. Kumar stated, "This is the first patent to issue of several patents that we expect to issue garnering protection of our cancer detection technology. The claims of this patent were allowed in May of 2017, and now we have received the official issuance notification and patent number. We currently have one other key patent application pending at the USPTO and expect to file for additional patent protection as our research and development continues."

- Lefamulin met all primary FDA and EMA endpoints with a favorable tolerability profile -  

- Conference call and webcast today at 8:30 a.m. EDT to review results -

 

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Sept. 18, 2017  -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced positive topline results from the lefamulin evaluation against pneumonia (LEAP 1) trial,  which evaluated the safety and efficacy of intravenous (IV) to oral lefamulin in patients with community-acquired bacterial pneumonia (CABP).  CABP is the leading cause of infectious death in the United States.

Updated Data Highlighted in Poster Presentation at 10th International Meeting of Pediatric Endocrinology

Phase III Study Expected to Begin by End of 2017

 

REDWOOD CITY, Calif., Sept. 15, 2017  -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that updated safety and efficacy data from the pilot clinical trial of Diazoxide Choline Controlled Release Tablet (DCCR) for the treatment of Prader-Willi syndrome (PWS) were the subject of a poster presentation at the 10th International Meeting of Pediatric Endocrinology, being held September 14-17 in Washington, D.C.  The data were presented by Virginia Kimonis, M.D., Division of Genetics and Metabolism, School of Medicine, University of California, Irvine, and Principal Investigator of the trial.

SAN DIEGO, Sept. 14, 2017  -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today it licensed its ENHANZE® drug-delivery technology to Roche for exclusive development of an undisclosed therapeutic target.

 

Under terms of the agreement, Halozyme will receive an initial $30 million with the potential to earn additional payments of up to $160 million subject to achievement of specified development, regulatory and sales-based milestones. Halozyme will also receive tiered, mid-single digit royalties on sales of commercialized products.